GLOW vs KLOW Peptide Stack: Ingredients and Combination Evidence

KLOW is GLOW with one added ingredient. Both blends center on GHK-Cu, BPC-157 and TB-500, and KLOW adds KPV for anti-inflammatory signaling. Neither blend has been studied as a blend, so what you can learn comes from research on each ingredient alone. GHK-Cu has the most skin research, BPC-157 recovery signals come mostly from rodents, and KPV inflammation data come from mouse gut studies.

What is different between GLOW and KLOW?

GLOW combines three peptides. GHK-Cu is a copper-binding peptide linked to skin and connective tissue repair, while BPC-157 and TB-500 are studied for tissue repair. KLOW includes that same trio and adds KPV, a three-amino-acid piece (Lys-Pro-Val) from the tail end of alpha-MSH, a natural hormone involved in inflammation signaling blend comparison.

Common listings describe GLOW vials as 50 mg GHK-Cu with 10 mg BPC-157 and 10 mg TB-500, and KLOW as that same base with 10 mg KPV added blend comparison. The extra ingredient does not change the base. It adds a separate focus on anti-inflammatory signaling.

Have these blends been tested together?

No controlled study has tested GLOW or KLOW as a combined blend. An orthopedic overview notes recovery claims for BPC-157 and TB-500 rest almost entirely on animal models clinic overview, and a 2025 systematic review of BPC-157 found the human record limited to a small retrospective chart review systematic review.

For recovery, single-ingredient results do not equal combined results. You cannot assume what three or four ingredients do together from what each one did alone.

What has each part shown on its own?

GHK-Cu has the clearest skin signals. Lab, animal and small human topical work link it to more collagen, elastin and supportive gel-like molecules in skin, plus support for dermal fibroblasts, the cells that maintain skin structure GHK-Cu review. Those findings describe skin repair. They did not measure muscle or joint recovery.

BPC-157 points more toward injury models, but mostly in rodents. Preclinical models report better tendon, ligament, muscle and bone healing, while the human record is limited to a small retrospective report of knee-pain relief after joint injection, with no clinical safety data systematic review.

KPV, the part that makes KLOW different, has the narrowest record. In two mouse models of bowel inflammation, treated mice recovered sooner and showed less inflammatory buildup in colon tissue mouse colitis study. Those gut findings in mice do not translate to injury recovery in women.

If faster recovery after training or a nagging injury is what you want, you can walk through your history and goals in the /quiz to see if an HOD plan fits.